Better EFS Outcomes with Perioperative Durvalumab Plus FLOT Than with Placebo Plus FLOT for Resectable Gastric or GEJ Adenocarcinoma By Ogkologos - June 10, 2025 722 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MATTERHORN study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Camizestrant ESMO Calls for the Ring-Fenced Funding of Health Under the 2028-2034 Long-Term Budget of the EU, the Multiannual Financial Framework (MFF) New ESMO President 2029-2030 Elected MOST POPULAR How the Cancer Community Can Help Close the Care Gap This... February 4, 2022 Cancer in My Community: Advancements in Cancer Care in Singapore December 2, 2021 How “the most advanced machine learning approach” is finding new cancer-causing... October 12, 2022 Oxaliplatin-Based Adjuvant Chemotherapy Shows Good Tolerance and Similar Time To Recurrence... April 4, 2024 Load more HOT NEWS Some Children with Wilms Tumor Can Receive Less Therapy, Study Suggests 20 years on: how we’ve decreased cancer death rates A bug in the system – the difficulties of linking the... 25-Year-Old Mom Had Chemo & Surgery, Then Was Told She Never...
